New Drug Candidate Targets Capillary No-Reflow in Heart Attack Treatment
What happened
A study published in Nature details a new therapeutic strategy for Capillary No-Reflow (CNR), a condition that prevents blood flow restoration even after coronary arteries are reopened. Researchers identified a smooth-muscle-myosin inhibitor that relaxes pathological hypercontractions in capillaries. This work led to the creation of CLN-2501, described as the first Capillary-Selective Vasodilator.
From prnewswire.com
Why it matters
CNR affects a majority of STEMI Acute Myocardial Infarction patients, leading to larger heart tissue death and worse survival rates. Since there is currently no approved therapy specifically targeting CNR, the advancement of CLN-2501 represents a significant step toward treating this major unresolved problem in cardiac care.
From prnewswire.com
Who's involved
- András Málnási-CsizmadiaBiochemist whose research led to the identification of the smooth-muscle-myosin inhibitor.
- Harvard Medical SchoolMedical school involved in the research collaboration.
- Baim Institute for Clinical ResearchNonprofit organization involved in the clinical research collaboration.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Baim Institute for Clinical ResearchSpeculative
The Baim Institute for Clinical Research might see increased funding pathways due to the validation of its research direction.
- Harvard Medical SchoolSpeculative
Harvard Medical School could see enhanced institutional prestige and investment due to the major scientific breakthrough.
Keep exploring
The entities involved
-
Boston
capital and largest city of Massachusetts, United States
-
Harvard Medical School
medical school in Boston, Massachusetts